<DOC>
	<DOCNO>NCT03036891</DOCNO>
	<brief_summary>The objective study evaluate effect naloxegol ( peripheral mu-opioid receptor antagonist [ PAMORA ] ) opioid-related gastroparesis 1 ) symptom gastroparesis ; 2 ) gastric empty ; 3 ) pain control . The endpoint gastroparesis symptom ( PAGI-SYM ) , gastric emptying ( GEBT ) , pain control ( McGill Pain Inventory ) . The hypothesis test naloxegol improves symptom gastroparesis patient take opioids well improve gastric empty maintain control patient 's pain . This study entail initial double-blind , randomize , placebo-controlled , 4-week treatment period naloxegol vs placebo patient opioid-related gastroparesis follow 4-week open label period demonstrate improvement symptom gastric empty naloxegol .</brief_summary>
	<brief_title>Naloxegol Opioid-Related Gastroparesis</brief_title>
	<detailed_description>Medicines delay gastric empty produce similar symptom gastroparesis . In particular , narcotic analgesic , produce gastroparesis picture , delay gastric emptying . The slow effect opioids gastric , small bowel , colonic motility well characterize . Unfortunately , many patient stop pain medication due underlying condition , back pain , fibromyalgia . On top , narcotic reduce effectiveness prokinetics agent use treat gastroparesis , metoclopramide domperidone . At time , good treatment gastroparesis , especially opioid-related gastroparesis . Data suggest relationship opioid use decrease gastric motility . Literature suggest peripherally act opioid agonist may provide relief instance GI dysfunction ( Holzer 2007 ) . Movantik ( Naloxegol ) opioid agonist specifically design work outside central nervous system . Movantik ( Naloxegol ) alleviate adverse effect associate chronic pain patient opioid treatment - reduction undesired peripheral effect opioids without disrupt analgesic effect . The use Movantik ( Naloxegol ) potential improve gastric dysmotility preserve pain relief opioid analgesic . The objective study evaluate effect naloxegol opioid-related gastroparesis . This randomized , double-blind study compare Movantik 25 mg placebo . The dose Movantik dose currently FDA approve opioid-induced constipation . The four-week study period duration phase 2b study Movantik opioid-induced constipation response rate 60 % 35 % active treatment placebo ( Chey 2015 ) . The investigator include unique aspect study well balance benefit patient participate randomize double-blind study half patient receive placebo agent . All patient treatment group placebo group invite participate 4-week open-label extension study . This also serve study duration potential favorable effect Movantik ( Naloxegol ) patient population well offer extended time period ass safety tolerability .</detailed_description>
	<mesh_term>Gastroparesis</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Naloxegol</mesh_term>
	<criteria>1 . Age 1884 , Males Females 2 . Daily use narcotic analgesic treatment pain . Patients need stable daily dose opiate last 4 week prior enrollment 3 . Patients symptoms gastroparesis GCSI score ( PAGISYM ) &gt; 2.0 . These symptom gastroparesis must present start opioid treatment . 4 . Delayed gastric empty base previous scintigraphy ( Percent gastric retention &gt; 60 % 2 hour and/or &gt; 10 % retention 4 hour 5 . Signing informed consent prior study specific procedures 1 . Prior gastric resective surgery bariatric surgery , antrectomy . 2 . Presence severe renal impairment ( CrCl &lt; 60 ml/min ) 3 . Presence severe hepatic impairment ChildPugh Classification Class C , generally AST &gt; 200 ALT &gt; 200 Total bilirubin &gt; 3.0 . 4 . Other condition besides gastroparesis could potentially slow gastric emptying , untreated hypothyroidism . 5 . Concomitants use strong CYP 3A4 inhibitor ( ketoconazole , diltiazem , erythromycin , clarithromycin ) , use CYP3A4 inducer . 6 . Use NSAIDs and/or Plavix/Clopidogrel 7 . Any prior use Movantik ( study drug ) opioid receptor antagonist ( e.g. , Relistor ( methylnaltrexone ) , naltrexone , naloxone ) screen visit . 8 . Patients known cancer cancer history within last 5 year prior screen visit . 9 . Patients GI obstruction and/or perforation condition potential GI perforation . 10 . Patients disruption bloodbrain barrier ; 11 . Current use medication affect gastric motility metoclopramide , domperidone , erythromycin ; 12 . Pregnant woman , female plan become pregnant , nursing mother . 13 . Women childbearing potential unwilling use contraceptive throughout course treatment 14 . Subjects severe comorbidities ( Cardiovascular , respiratory , renal , hepatic , hematologic , endocrine , neurologic ) base PI 's clinical judgment . 15 . Active substance abuse . 16 . History major comorbid psychiatric condition include mania schizophrenia severe current depression 17 . Atrisk population , include prisoner mentally challenge . Any condition patient situation may put him/her significant risk , may confound study result , may interfere significantly subject 's participation study ( e.g. , difficulty hearing , cognitive impairment ) 18 . Patients Movantik clinically inadvisable 19 . Subject unable consent unwilling provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Gastroparesis</keyword>
	<keyword>Opioid-Induced</keyword>
	<keyword>Delayed Gastric Emptying</keyword>
</DOC>